Articles by Jacob Austin-Breneman in JoVE
Working with Human Tissues for Translational Cancer Research Alexandre Reuben*1, Vancheswaran Gopalakrishnan*1, Heidi E. Wagner3, Christine N. Spencer2, Jacob Austin-Breneman1, Hong Jiang1, Zachary A. Cooper1, Jennifer A. Wargo1 1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 2Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, 3Department of Pathology and Institutional Tissue Bank, University of Texas MD Anderson Cancer Center Translational cancer research is dependent on extraction of human tissues. Much work has gone into optimizing extraction methods for ex vivo analysis. Here, we describe tissue processing methods allowing for maximal data output from limited samples.
Other articles by Jacob Austin-Breneman on PubMed
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2015 | Pubmed ID: 26025561 BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.